Iright
BRAND / VENDOR: CST

CST, 4816S, RANK Ligand (L300) Antibody

CATALOG NUMBER: 4816S
Regular price$0.99
/
Shipping calculated at checkout.
  • ddddd

    99 xxxxxx

  • Backordered, shipping soon

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Product Description
Polyclonal Antibody for studying TNFSF11. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, RANK Ligand (L300) Antibody (CST #4816) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity RANK Ligand (L300) Antibody detects transfected levels of cellular RANK Ligand protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxyl terminus of human RANK Ligand. Antibody was purified by protein A and peptide affinity chromatography. Background RANK (receptor activator of NF-κB) is a member of the tumor necrosis factor (TNF) receptor subfamily that is activated by its ligand, RANKL (TRANCE/OPGL/ODF), to promote survival of dendritic cells and differentiation of osteoclasts (1-4). Although RANK is widely expressed, its cell surface expression may be more restricted to dendritic cells and foreskin fibroblasts (1). RANK contains a 383-amino acid intracellular domain that associates with specific members of the TRAF family to NF-κB and JNK activation (1,5). RANKL/RANK signaling may also lead to survival signaling through activation of the Akt pathway and an upregulation of survival proteins, including Bcl-xL (2,6). RANK signaling has been implicated as a potential therapeutic to inhibit bone loss and arthritis (7,8). RANKL (1), also named TNF-related activation-induced cytokine (TRANCE) (2,9), osteoprotegerin ligand (OPGL) (3), osteoclast differentiation factor (ODF) (4), and TNFSF11, is a type II transmembrane protein of the TNF family that exists as both a membrane-bound and soluble form. It is an essential regulator of immune function and bone development and homeostasis (7,10,11). RANKL is predominately expressed in activated T cells, as well as the thymus, lymph node, and bone marrow and promotes dendritic cell survival. Deletion of RANKL in mice leads to severe osteoporosis with a loss of osteoclasts, defects in T and B cell differentiation, loss of lymph node development, and mammary gland development during pregnancy (12-14). Alternate Names CD254; hRANKL2; ODF; OPGL; OPTB2; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; receptor activator of nuclear factor kappa B ligand; Receptor activator of nuclear factor kappa-B ligand; sOdf; TNF superfamily member 11; TNF-related activation-induced cytokine; TNF11; TNFSF11; TNLG6B; TRANCE; tumor necrosis factor (ligand) superfamily, member 11; tumor necrosis factor ligand 6B; Tumor necrosis factor ligand superfamily member 11; Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form; tumor necrosis factor superfamily member 11 Specification REACTIVITY: H SENSITIVITY: Transfected Only MW (kDa): 35-45 SOURCE: Rabbit

Order Guidelines

1. Price & Stock Available on Request. 📧Click to send email to: service@iright.com

2. Please DO NOT make payment before confirmation.

3. Minimum order value of $1,000 USD required.

Collaboration

Tony Tang

📧Email: Tony.Tang@iright.com

📱Mobile/WhatsApp/Wechat: +86-17717886924